XW-032 is an apo-IDO1 inhibitor with an IC50 of 21 nM. In the CT26 syngeneic mouse model, XW-032 demonstrates significant in vivo antitumor efficacy with a TGI of 63%, showing potential for cancer research applications.
Target:
IDO,Indoleamine 2,3-Dioxygenase (IDO)
* VAT and and shipping costs not included. Errors and price changes excepted
